2016_Head & Neck COURSE BOOK

Stage III/IV: curative intention Recurrent/metastatic: first-line

Study

N Regimens

Median PFS

Median Survival

Vermorken NEJM 2008 220 222 Platin/5-Fluorouracil versus Vermorken Lancet Oncol 2013 330 327 Cisplatin/5-Fluorouracil versus

Platin/5-FU/cetuximab 3.3 months* 5.6 months* 7.4 months* 10.1 months* Cisplatin/5-FU/panitumumab 4.6 months* 5.8 months* 9 months 11.1 months

* Statistically significa